Consumer medicine information

Tetanus Immunoglobulin-VF (for intramuscular injection)

Immunoglobulin, tetanus


Brand name

Tetanus Immunoglobulin-VF (For Intramuscular Use)

Active ingredient

Immunoglobulin, tetanus




Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Tetanus Immunoglobulin-VF (for intramuscular injection).

What is in this leaflet

This leaflet answers some common questions about Tetanus Immunoglobulin-VF. It does not contain complete information about Tetanus Immunoglobulin-VF. It does not take the place of talking to your doctor.

If you have any concerns about using this medicine, ask your doctor. Follow your doctor’s advice even if it is different from what this leaflet says.

Please read this leaflet carefully and keep it for future reference.

The information in this leaflet is subject to change. Please check with your doctor whether there is any new information about this medicine that you should know since you were last treated.

What Tetanus Immunoglobulin-VF is used for

Tetanus Immunoglobulin-VF is manufactured from human plasma (the liquid component of blood) collected by Australian Red Cross Lifeblood. Tetanus Immunoglobulin-VF contains protein substances called antibodies which can provide protection against tetanus infection. It is used for the prevention of tetanus in a person who has not recently been immunised against tetanus and who has suffered an injury which could expose them to the tetanus bacteria.

Ask your doctor if you have any questions about why Tetanus Immunoglobulin-VF has been prescribed for you. Your doctor will have assessed the risks and benefits associated with the use of this product for you.

Before you are given Tetanus Immunoglobulin-VF

Tetanus Immunoglobulin-VF must not be used if you have a history of allergy to this product.

Tell your doctor if you have allergies to any other medicines or if you have ever had an allergic reaction to an injection.

Tell your doctor also if you:

  • have ever had a tetanus vaccine injection
  • have previously been advised that you have immunoglobulin A (IgA) deficiency
  • are taking or using any other medicines. These include medicines bought from pharmacies, supermarkets and health food stores.
  • suffer from a blood disorder or blood clotting problem
  • have had any vaccination during the last two weeks
  • have any other medical conditions.

Pregnant or lactating women should discuss use of Tetanus Immunoglobulin-VF with their doctor.

About blood products

When products are made from human blood and injected into you, it is possible that viruses or other substances could be present in the product and cause an illness. These could be viruses such as hepatitis, human immunodeficiency virus (HIV), or human parvovirus B19 and theoretically the Creutzfeldt-Jakob Disease (CJD) agent. There could also be other infectious agents some of which may not as yet have been discovered.

To reduce the risk of this happening, extra steps are taken when manufacturing this product. Strict controls are applied to the selection of blood donors and donations. The product is specially treated to remove and kill certain viruses. These special treatments are considered effective against viruses known as enveloped viruses such as HIV, hepatitis B virus and hepatitis C virus, and non-enveloped viruses, such as hepatitis A virus and human parvovirus B19. Additionally, the product contains specific antibodies which can provide some protection against human parvovirus B19. Despite these measures, the risk of viral and other agent’s infectivity cannot be totally eliminated.

Vaccines are available against some of these viruses and your doctor will be able to help you decide whether it is worthwhile having any of those vaccines.

Please discuss the risks and benefits of this product with your doctor.

How to use Tetanus Immunoglobulin-VF

Your doctor will determine the dose(s) of Tetanus Immunoglobulin-VF that you are to receive. Your doctor will give you the injection. It will be injected into the muscle. If a large volume of product is required, you may receive more than one injection.

Side effects

Along with their intended effects, medicines may cause some unwanted effects, which can sometimes be serious. Furthermore, individual patients may react differently to the same dose of the same medicine. This applies to Tetanus Immunoglobulin-VF.

Reactions are very uncommon after injection with Tetanus Immunoglobulin-VF. However, some pain, redness and stiffness may be apparent at the injection site. This may occur after any large injection into a muscle.

Occasionally mild fever, chills, drowsiness or discomfort may be felt and an itchy rash may develop.

If any of these effects are severe, or if you are worried about any other symptoms after the injection, consult your doctor.

Tetanus Immunoglobulin-VF can interfere with some live vaccines (e.g. measles and polio), even up to three months later. Advise your doctor if you are to receive other vaccines within three months of receiving Tetanus Immunoglobulin-VF.


The consequences of overdosage are not known.

Storing Tetanus Immunoglobulin-VF

Store at 2°C to 8°C (Refrigerate. Do not freeze). Protect from light.

Do not use after the expiry date shown on the label.

Further information

Tetanus Immunoglobulin-VF can only be obtained on a doctor’s prescription. This leaflet does not contain the complete information about Tetanus Immunoglobulin-VF. If you require further information about Tetanus Immunoglobulin-VF and your treatment generally, or if you have any questions or are not sure about something in this leaflet, consult your doctor.

Product description

What it looks like

Tetanus Immunoglobulin-VF is a clear, colourless, viscous (thick) solution. It is available in glass bottles.


Each bottle of Tetanus Immunoglobulin-VF is a sterile solution containing 160 mg/mL blood proteins of which at least 98% is immunoglobulins. It also contains 22.5 mg/mL glycine.


Tetanus Immunoglobulin-VF is manufactured in Australia by:

CSL Behring (Australia) Pty Ltd
ABN 48 160 734 761
189-209 Camp Road
Broadmeadows VIC 3047


Australian Red Cross Lifeblood

Date of revision

May 2020

Australian Register Number
AUST R 61218

Published by MIMS June 2020


Brand name

Tetanus Immunoglobulin-VF (For Intramuscular Use)

Active ingredient

Immunoglobulin, tetanus





Distributed by Australian Red Cross Lifeblood

1 Name of Medicine

Human tetanus immunoglobulin.

6.7 Physicochemical Properties

Chemical structure.

Not applicable.

CAS number.

None assigned.

2 Qualitative and Quantitative Composition

Tetanus Immunoglobulin-VF is a sterile, preservative free solution containing 160 mg/mL human plasma proteins and 22.5 mg/mL glycine. At least 98% of the protein is immunoglobulins (mainly IgG), with a tetanus antitoxin activity of not less than 100 IU/mL.
Tetanus Immunoglobulin-VF is manufactured from human plasma collected by Australian Red Cross Lifeblood.

3 Pharmaceutical Form

Solution for intramuscular injection.
The solution has a pH of 6.6.

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Tetanus Immunoglobulin-VF contains high levels of antibodies (mainly IgG) against tetanus toxin. Donations are selected on the basis that they contain high levels of specific antibodies against the toxin of Clostridium tetani.

Clinical trials.

A comparative clinical trial was conducted to investigate the effect of pasteurisation on the in vivo behaviour of intramuscular immunoglobulins using hepatitis B immunoglobulin (pasteurised and unpasteurised) as the representative of this group of products. Fifty eight (58) healthy subjects (28 males and 30 females) each received an intramuscular injection of pasteurised (viral inactivated) or unpasteurised hepatitis B immunoglobulin. No significant differences were observed.
Twenty eight (28) subjects received the viral inactivated product. Maximal serum concentration of IgG was reached after 8.0 ± 5.5 days (mean ± SD), and the estimated half-life of IgG was 27.2 ± 6.6 days (mean ± SD). These values are consistent with ranges observed with other intramuscular immunoglobulin products.
A clinical trial with Tetanus Immunoglobulin-VF has not been conducted.

5.2 Pharmacokinetic Properties

See Section 5.1 Pharmacodynamic Properties.

5.3 Preclinical Safety Data


No genotoxicity studies have been conducted with Tetanus Immunoglobulin-VF. There have been no reports of such effects associated with the use of CSL's plasma-derived therapeutic medicines.


No carcinogenicity studies have been conducted with Tetanus Immunoglobulin-VF. There have been no reports of such effects associated with the use of CSL's plasma-derived therapeutic medicines.

4 Clinical Particulars

4.1 Therapeutic Indications

Tetanus Immunoglobulin-VF is indicated for the passive protection of individuals who have sustained a tetanus prone wound and who have either not been actively immunised against tetanus or whose immunisation history is doubtful. It should also be given to the fully immunised patient with a tetanus prone wound if more than ten years have elapsed since the last vaccine dose. In all the above instances, active immunisation with a tetanus vaccine should be commenced at the same time (see Table 1) according to current recommendations. Although Tetanus Immunoglobulin-VF and vaccine can be given at the same time, they should be administered in opposite limbs, using separate syringes.

4.3 Contraindications

Tetanus Immunoglobulin-VF is contraindicated in individuals:
1. With isolated immunoglobulin A (IgA) deficiency, unless they have been tested and shown not to have circulating anti-IgA antibodies.
2. Who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.

4.4 Special Warnings and Precautions for Use

Tetanus Immunoglobulin-VF (For Intramuscular Use) must not be administered intravenously because of the potential for anaphylactic reactions. Injections must be made intramuscularly, and care should be taken to draw back on the plunger of the syringe before injection in order to be certain that the needle is not in a blood vessel, (Tetanus Immunoglobulin for intravenous use is available when an intravenous product is required.)
Tetanus Immunoglobulin-VF should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. In the case of shock, treatment should follow the guidelines of shock therapy.

Pathogen safety.

This product is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses and theoretically Creutzfeldt-Jakob Disease (CJD) agents, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.
In addition, the manufacturing process for Tetanus Immunoglobulin-VF contains specific steps to reduce the possibility of viral transmission including pasteurisation for viral inactivation and nanofiltration for virus removal. The current procedures applied in the manufacture of this product are effective against enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and the nonenveloped viruses, such as hepatitis A virus (HAV) and human parvovirus B19. Additionally, the product contains specific antibodies directed against human parvovirus B19.
There is no evidence to date that parvovirus B19 can be transmitted by Tetanus Immunoglobulin-VF (IM), which is known to contain antibodies to the virus and the nanofiltration step of the manufacturing process has been shown to remove such viruses (or viruses of similar size).
Immunoglobulins for intramuscular injection, prepared by this process from plasma screened by current methods, have not been implicated in the transmission of viral infectious diseases including human immunodeficiency virus (HIV). Studies using plasma spiked with HIV have shown that the Cohn cold-ethanol fractionation process produces a very large reduction in virus titre with undetectable levels in the immunoglobulin fraction. Epidemiological studies have not recognised any cluster of AIDS patients or HIV seroconversion in immunoglobulin recipients.
Despite these measures, such products may still potentially transmit disease. There is also the possibility that other known or unknown infectious agents may be present in such products.
Vaccination for patients in receipt of medicinal products from human plasma should be considered where appropriate.

Use in the elderly.

The use of this product in the elderly population has not been established in appropriate studies. To date, this population is not over-represented in spontaneous reports of adverse events associated with the use of CSL's intramuscular immunoglobulin products.

Paediatric use.

The use of this product in the paediatric population has not been established in appropriate studies. To date, this population is not over-represented in spontaneous reports of adverse events associated with the use of CSL's intramuscular immunoglobulin products.

Effects on laboratory tests.

After injection of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Tetanus Immunoglobulin-VF should not be mixed with other pharmaceutical products, except as indicated (see Section 4.2 Dose and Method of Administration).

Live attenuated virus vaccines.

Passively acquired antibody can interfere with the response to live, attenuated virus vaccines. Therefore, administration of such vaccines, e.g. poliomyelitis or measles, should be deferred until approximately three months after passive immunisation.

Inactivated vaccines.

Inactivated vaccines may be administered concurrently with passive antibody (although in separate syringes) to induce active immunity as is sometimes done for tetanus prone wounds.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No reproductive toxicity studies have been conducted with Tetanus Immunoglobulin-VF (IM). There have been no reports of effects on fertility associated with the use of CSL's plasma-derived therapeutic medicines.
The safety of Tetanus Immunoglobulin-VF (IM) for use in human pregnancy has not been established in controlled clinical trials and therefore it should only be given to pregnant women with caution.
The safety of Tetanus Immunoglobulin-VF (IM) during lactation has not been established in controlled clinical trials and therefore it should only be given to breastfeeding mothers with caution. Immunoglobulins are excreted in breast milk, however, it is not known whether this applies to passively administered Tetanus Immunoglobulin-VF.

4.8 Adverse Effects (Undesirable Effects)

Local tenderness, erythema and stiffness may occur at the site of injection and may persist for several hours. This may occur after any intramuscular injection. In the clinical trial with hepatitis B immunoglobulin, the following general and local reactions were recorded in the 58 healthy subjects (total number of events, up to and including seven days postinjection; pasteurised/unpasteurised product): malaise (20/22 events), drowsiness (13/17 events), induration (10/4 events), sensation of fever (4/4 events), chills (3/3 events), sweating (3/1 events) and warmth/heat when touched (0/4 events). There was an overall higher reporting of local tolerance adverse events at the injection site for the unpasteurised product, such as pain (32/52 events), bruising (10/22 events), redness (2/8 events) and irritation (2/4 events).
Mild pyrexia, malaise, drowsiness and urticaria have been reported occasionally after injections of immunoglobulins. True allergic responses are rare. Skin lesions, headache, dizziness, nausea, generalised hypersensitivity reactions and convulsions have been reported on rare occasions.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions at

4.2 Dose and Method of Administration


Good medical care is essential in the prevention of tetanus from fresh wounds. Thorough cleansing and removal of all foreign and necrotic material from the site of injury is important.
The minimum routine prophylactic dose of Tetanus Immunoglobulin-VF (For Intramuscular Use) for adults or children is 250 IU. The dose should be doubled if the wound is grossly contaminated or if more than 24 hours have elapsed between wounding and the seeking of medical attention.


If the product appears to be turbid by transmitted light or contains any sediment it must not be used. The product does not contain an antimicrobial preservative. It must, therefore, be used immediately after opening the vial. Any unused solution must be discarded appropriately.
Tetanus Immunoglobulin-VF should be brought to room temperature before use, and given slowly by deep intramuscular injection using an appropriate sized needle. If a large dose (more than 5 mL) is required, it is advisable to administer it in divided doses at different sites. Hyaluronidase and/or a suitable local anaesthetic may be added to the injection if desired.
An intravenous preparation of tetanus immunoglobulin (Tetanus Immunoglobulin for Intravenous Use) is available for patients where large doses are indicated (i.e. treatment of tetanus), or when the patient has a significant haemostatic defect which may cause bleeding following intramuscular injection.

4.7 Effects on Ability to Drive and Use Machines

No effects on ability to drive and use machines have been observed.

4.9 Overdose

The consequences of overdosage are not known.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

7 Medicine Schedule (Poisons Standard)


6 Pharmaceutical Particulars

6.1 List of Excipients

See Section 2 Qualitative and Quantitative Composition.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store at 2°C to 8°C. (Refrigerate. Do not freeze.) Protect from light. Do not use after the expiry date shown on the label.

6.5 Nature and Contents of Container

Tetanus Immunoglobulin-VF solution for intramuscular injection is available in single vials containing 250 IU human tetanus antitoxin. The actual volume in the vial is stated on the label.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

Summary Table of Changes